Advances in stem cell research for the treatment of primary hypogonadism

Volume: 18, Issue: 8, Pages: 487 - 507
Published: Jun 29, 2021
Abstract
In Leydig cell dysfunction, cells respond weakly to stimulation by pituitary luteinizing hormone, and, therefore, produce less testosterone, leading to primary hypogonadism. The most widely used treatment for primary hypogonadism is testosterone replacement therapy (TRT). However, TRT causes infertility and has been associated with other adverse effects, such as causing erythrocytosis and gynaecomastia, worsening obstructive sleep apnoea and...
Paper Details
Title
Advances in stem cell research for the treatment of primary hypogonadism
Published Date
Jun 29, 2021
Volume
18
Issue
8
Pages
487 - 507
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.